141 related articles for article (PubMed ID: 7524769)
1. Molecular mapping of the Cromer blood group Cra and Tca epitopes of decay accelerating factor: toward the use of recombinant antigens in immunohematology.
Telen MJ; Rao N; Udani M; Thompson ES; Kaufman RM; Lublin DM
Blood; 1994 Nov; 84(9):3205-11. PubMed ID: 7524769
[TBL] [Abstract][Full Text] [Related]
2. Glycosyl phosphatidylinositol-linked blood group antigens and paroxysmal nocturnal hemoglobinuria.
Telen MJ
Transfus Clin Biol; 1995; 2(4):277-90. PubMed ID: 8542026
[TBL] [Abstract][Full Text] [Related]
3. Molecular basis of Cromer blood group antigens.
Lublin DM; Kompelli S; Storry JR; Reid ME
Transfusion; 2000 Feb; 40(2):208-13. PubMed ID: 10686005
[TBL] [Abstract][Full Text] [Related]
4. Molecular basis of reduced or absent expression of decay-accelerating factor in Cromer blood group phenotypes.
Lublin DM; Mallinson G; Poole J; Reid ME; Thompson ES; Ferdman BR; Telen MJ; Anstee DJ; Tanner MJ
Blood; 1994 Aug; 84(4):1276-82. PubMed ID: 7519480
[TBL] [Abstract][Full Text] [Related]
5. Dr(a-) polymorphism of decay accelerating factor. Biochemical, functional, and molecular characterization and production of allele-specific transfectants.
Lublin DM; Thompson ES; Green AM; Levene C; Telen MJ
J Clin Invest; 1991 Jun; 87(6):1945-52. PubMed ID: 1710232
[TBL] [Abstract][Full Text] [Related]
6. Hemagglutination inhibition of Cromer blood group antibodies with soluble recombinant decay-accelerating factor.
Daniels GL; Green CA; Powell RM; Ward T
Transfusion; 1998 Apr; 38(4):332-6. PubMed ID: 9595014
[TBL] [Abstract][Full Text] [Related]
7. Mapping of epitopes, glycosylation sites, and complement regulatory domains in human decay accelerating factor.
Coyne KE; Hall SE; Thompson S; Arce MA; Kinoshita T; Fujita T; Anstee DJ; Rosse W; Lublin DM
J Immunol; 1992 Nov; 149(9):2906-13. PubMed ID: 1383332
[TBL] [Abstract][Full Text] [Related]
8. Identification of human erythrocyte blood group antigens on decay-accelerating factor (DAF) and an erythrocyte phenotype negative for DAF.
Telen MJ; Hall SE; Green AM; Moulds JJ; Rosse WF
J Exp Med; 1988 Jun; 167(6):1993-8. PubMed ID: 2455016
[TBL] [Abstract][Full Text] [Related]
9. Molecular cloning and characterization of decay-accelerating factor deficiency in Cromer blood group Inab phenotype.
Wang L; Uchikawa M; Tsuneyama H; Tokunaga K; Tadokoro K; Juji T
Blood; 1998 Jan; 91(2):680-4. PubMed ID: 9427725
[TBL] [Abstract][Full Text] [Related]
10. Three new high-prevalence antigens in the Cromer blood group system.
Hue-Roye K; Lomas-Francis C; Belaygorod L; Lublin DM; Barnes J; Chung A; Fung-Kee-Fung K; Kinney J; Goldman-Lavi R; Yahalom V; Poole J; Ivankovic Z; Alcantara D; Bekavac M; Cepulic BG; Velliquette RW; Mason R; Reid ME
Transfusion; 2007 Sep; 47(9):1621-9. PubMed ID: 17725726
[TBL] [Abstract][Full Text] [Related]
11. Decay-accelerating factor (CD55) deficiency phenotypes in Japanese.
Daniels GL; Green CA; Mallinson G; Okubo Y; Hori Y; Kataoka A; Kaihara M
Transfus Med; 1998 Jun; 8(2):141-7. PubMed ID: 9675792
[TBL] [Abstract][Full Text] [Related]
12. Disappearance of antibodies to Cromer blood group system antigens during mid pregnancy.
Reid ME; Chandrasekaran V; Sausais L; Pierre J; Bullock R
Vox Sang; 1996; 71(1):48-50. PubMed ID: 8837357
[TBL] [Abstract][Full Text] [Related]
13. A monoclonal antibody against human decay-accelerating factor (DAF, CD55), D17, which lacks reactivity with semen-DAF.
Hara T; Matsumoto M; Fukumori Y; Miyagawa S; Hatanaka M; Kinoshita T; Seya T; Akedo H
Immunol Lett; 1993 Aug; 37(2-3):145-52. PubMed ID: 7505002
[TBL] [Abstract][Full Text] [Related]
14. Cromer-related antigens--blood group determinants on decay-accelerating factor.
Daniels G
Vox Sang; 1989; 56(4):205-11. PubMed ID: 2474898
[TBL] [Abstract][Full Text] [Related]
15. Use of the MAIEA technique to confirm the relationship between the Cromer antigens and decay-accelerating factor and to assign provisionally antigens to the short-consensus repeats.
Petty AC; Daniels GL; Anstee DJ; Tippett P
Vox Sang; 1993; 65(4):309-15. PubMed ID: 7508660
[TBL] [Abstract][Full Text] [Related]
16. GUTI: a new antigen in the Cromer blood group system.
Storry JR; Sausais L; Hue-Roye K; Mudiwa F; Ferrer Z; Blajchman MA; Lublin DM; Ma BW; Miquel JF; Nervi F; Pereira J; Reid ME
Transfusion; 2003 Mar; 43(3):340-4. PubMed ID: 12675719
[TBL] [Abstract][Full Text] [Related]
17. The Cromer blood group system: a review.
Storry JR; Reid ME; Yazer MH
Immunohematology; 2010; 26(3):109-18. PubMed ID: 21214297
[TBL] [Abstract][Full Text] [Related]
18. The Cromer blood group system: an update.
Storry JR; Lomas-Francis C
Immunohematology; 2021 Sep; 37(3):118-121. PubMed ID: 34591381
[TBL] [Abstract][Full Text] [Related]
19. Biochemical studies on red blood cells from a patient with the Inab phenotype (decay-accelerating factor deficiency).
Reid ME; Mallinson G; Sim RB; Poole J; Pausch V; Merry AH; Liew YW; Tanner MJ
Blood; 1991 Dec; 78(12):3291-7. PubMed ID: 1720702
[TBL] [Abstract][Full Text] [Related]
20. Mechanisms by which the surface expression of the glycosyl-phosphatidylinositol-anchored complement regulatory proteins decay-accelerating factor (CD55) and CD59 is lost in human leukaemia cell lines.
Hatanaka M; Seya T; Matsumoto M; Hara T; Nonaka M; Inoue N; Takeda J; Shimizu A
Biochem J; 1996 Mar; 314 ( Pt 3)(Pt 3):969-76. PubMed ID: 8615796
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
